Recent CCCC News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 08:46:49 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 08:45:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 11:41:50 AM
- C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors • GlobeNewswire Inc. • 06/10/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 11:10:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 11:07:20 AM
- C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/29/2024 08:01:00 PM
- C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum • GlobeNewswire Inc. • 04/09/2024 11:00:00 AM
- C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 12:28:56 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 12:26:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 12:24:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 12:21:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 12:19:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:10:39 PM
- C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024 • GlobeNewswire Inc. • 03/05/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 12:05:34 PM
- C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins • GlobeNewswire Inc. • 03/04/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/22/2024 02:01:43 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 12:20:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 12:15:04 PM
- C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 10:07:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 10:05:14 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM